Keryx biopharmaceuticals inc (KERX)
Income statement / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Net U.S. Auryxia product sales
License
Cost of goods sold
Revenues:
Net U.S. Auryxia product sales

55,514

27,173

10,141

0

-

-

-

-

-

License revenue

5,127

4,810

3,539

10,825

7,000

-

5,000

0

21,616

Other revenue

-

-

-

-

-

-

-

-

3,575

Total revenues

60,641

31,983

13,680

10,825

7,000

-

5,000

0

25,191

Costs and expenses:
Cost of goods sold

21,955

37,803

4,520

0

-

-

-

-

-

License expense

3,076

2,886

2,124

495

-

-

-

-

-

Non-cash compensation

-

-

-

-

-

-

803

1,236

1,233

Other research and development

-

-

-

-

-

-

26,209

13,728

7,372

Research and development

37,679

29,504

36,694

51,502

34,734

20,031

27,012

14,964

8,605

Selling, general and administrative

99,622

84,553

81,410

70,057

19,349

7,048

-

-

-

Non-cash compensation

-

-

-

-

-

-

1,289

1,237

1,867

Other general and administrative

-

-

-

-

-

-

5,448

5,014

4,904

General and administrative

-

-

-

-

-

-

6,737

6,251

6,771

Total costs and expenses

162,332

154,746

124,748

122,054

54,083

27,079

33,749

21,215

15,376

Operating loss

-101,691

-122,763

-111,068

-111,229

-47,083

-27,079

-28,749

-21,215

9,815

Other income (expense):
Amortization of debt discount

62,965

34,227

11,357

0

-

-

-

-

-

Other income (expense), net

981

-4,025

-630

411

351

1,719

380

764

667

Total other income (expense)

-61,984

-38,252

-11,987

411

-

-

-

-

-

Loss before income taxes

-163,675

-161,015

-123,055

-110,818

-46,732

-25,360

-28,369

-20,451

10,482

Income tax expense (benefit)

-235

80

90

700

0

-

0

0

0

Loss from continuing operations

-

-

-

-

-

-

-28,369

-20,451

10,482

Gain from discontinued operations

-

-

-

-

-

-

246

120

3

Loss before extraordinary gain

-

-

-

-

-

-25,360

-28,123

-20,331

-

Extraordinary gain

-

-

-

-

-

2,639

-

0

-

Net loss

-163,440

-161,095

-123,145

-111,518

-46,732

-22,721

-28,123

-20,331

10,485

Loss before extraordinary gain

-

-

-

-

-

-0.36

-

-

-

Continuing operations

-

-

-

-

-

-

-0.42

-0.34

-

Discontinued operations

-

-

-

-

-

-

0.00

0.00

-

Extraordinary gain

-

-

-

-

-

0.04

-

0.00

-

Basic and diluted net loss per common share (in dollars per share)

-1.43

-1.52

-1.19

-1.23

-0.58

-0.32

-0.42

-0.34

-

Weighted average shares used in computing basic and diluted net loss per common share (in shares)

114,507

105,845

103,898

91,000

81,009

71,633

67,370

58,987

-

Continuing operations

-

-

-

-

-

-

-

-

0.21

Discontinued operations

-

-

-

-

-

-

-

-

0.00

Basic net (loss) income per common share

-

-

-

-

-

-

-

-

0.21

Continuing operations

-

-

-

-

-

-

-

-

0.21

Discontinued operations

-

-

-

-

-

-

-

-

0.00

Diluted net (loss) income per common share

-

-

-

-

-

-

-

-

0.21

Weighted average shares used in computing basic net (loss) income per common share

-

-

-

-

-

-

-

-

49,940

Weighted average shares used in computing diluted net (loss) income per common share

-

-

-

-

-

-

-

-

50,498